about
Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphomaStat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphomaNon random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia.Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing.Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemiaGenomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases.FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.Monosomal karyotype in myeloid neoplasias: a literature review.SETBP1 dysregulation in congenital disorders and myeloid neoplasms.PML-RARĪ± kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.Extramedullary disease in acute promyelocytic leukemia: two-in-one disease.The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32).Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation.Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.Systemic Mastocytosis with Associated Chronic Lymphocytic Leukemia: A Matter of Diseases or Prognostic Factors?5'RUNX1-3'USP42 chimeric gene in acute myeloid leukemia can occur through an insertion mechanism rather than translocation and may be mediated by genomic segmental duplications.Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation.A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia.SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemiaDeletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms.Retinal abnormalities in newly diagnosed adult acute myeloid leukemia.Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes.Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.Immunophenotypic and molecular features of 'cuplike' acute myeloid leukemias.Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints.A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
P50
Q28305360-49C821B7-3CE9-4581-9FB5-D21C9ACCF7F4Q33761711-29205E39-C5AC-498B-A3D4-E2DF67571261Q33919931-EE42CFA8-99C0-4B93-BDF0-86235381407EQ35525365-E0F040C4-0E7D-41FF-A5EC-553409E8B213Q36862301-DCE154FA-FFCB-4386-BFAD-88AA873E0040Q37326100-3774621D-8D92-4666-A123-467B4CF83B74Q37588786-03716B9D-DBF9-4EDA-9F35-606ED0E71209Q37699259-FAAB6E89-7363-4EA9-BE86-E6F1490BE9ACQ38485194-D25660D0-3378-4502-ABAC-297DAD3123DFQ38597391-35E825DC-1758-4D6A-837D-74547372DDB6Q38698612-30D29F46-0ECF-45A6-BF74-A8C1A80DF86EQ38701790-9B8D5B7B-7ED1-45C2-A853-4C24BD3A7A1EQ39276603-C9856E44-5679-4E5B-AFB2-E24ABCC753E4Q39284252-434A5D1E-3192-4E8F-94D5-DBFD622684C5Q39805430-8CC6484D-E6FC-4122-91C7-BFC0F58DFC11Q39924810-D80BA513-0F94-4C5D-B641-7A79E593F892Q40055693-DCD15FF2-AD49-4278-AE2E-7F7BCC0316DEQ40217698-9A83D363-F1D2-4A2A-AFED-F60BE8D6BB97Q40294208-926DB5C2-BE3A-44F8-828B-DAB66B9997F9Q40391981-A572DA28-ACE4-4C0D-827F-3E4498BB5BE4Q40449249-D0C58114-AF6A-4D70-AD05-D0B5A290F82AQ40821920-C9AC7F9D-61DC-4F27-AFA3-95F0F5DB231BQ40856474-C7B3A8C9-ADF8-45D8-A065-1DBF78E8D241Q40996735-B093D625-4999-4EF9-B161-AE047F0822C4Q41253739-3CE500B2-2658-494B-9DB0-39499B1BB794Q41789671-CBBA2EF9-519B-4F67-8E11-BC63FDD06714Q42128634-8A3C38ED-8B62-4A41-90BF-771ACC5850F2Q42277656-AB6BE9ED-9ED5-4C90-B1F3-B7C26B5C2144Q42426547-E48D2ABC-6AD9-4B34-9895-A1C77C0A6704Q43075393-D01BDFF1-BB26-4C18-8880-A9726AEEFF90Q43475684-616D9D72-D3F8-4CB2-9EFB-C66A5CEC0A79Q43670993-EB372F83-E701-4B81-AD63-103993032CD9Q43723492-DD574491-1A53-4E47-8889-0CB67DC7CCEAQ44908700-8781B988-605A-4609-B970-ECA905E01588Q45740186-D0754997-2696-4088-B8C7-CFE4DB2989BDQ45767654-B986E93F-B719-464F-AB08-24E9B6DDE431Q45956089-C83D4F91-E1F0-43C8-B823-158598644FA3Q47113340-4F6B3ADB-C1D6-4A58-A5D1-8958C207684CQ47243089-015E732C-7A55-4D5E-9677-E9F6F5CDF7D3Q47449330-3D8DFA26-D4A3-4F12-8F93-DAC006FD775B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Francesco Albano
@ast
Francesco Albano
@en
Francesco Albano
@es
Francesco Albano
@nl
Francesco Albano
@sl
type
label
Francesco Albano
@ast
Francesco Albano
@en
Francesco Albano
@es
Francesco Albano
@nl
Francesco Albano
@sl
prefLabel
Francesco Albano
@ast
Francesco Albano
@en
Francesco Albano
@es
Francesco Albano
@nl
Francesco Albano
@sl
P1053
J-2352-2016
P106
P1153
7003513795
P21
P31
P3829
P496
0000-0001-7926-6052